Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet)

doi:10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and
, Tuberculosis Network European Trials group (TBnet)

Sorbonne Université
Hôpital Avicenne
University of Bern
University of Namibia
Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy
University of Porto
Centro Hospitalar de Vila Nova de Gaia
National Tuberculosis Program
Centro de Investigação em Saude de Manhiça (CISM), Maputo, Mozambique
University of Barcelona
IRCCS Istituto per le Malattie Infettive Lazzaro Spallanzani - Roma
University of Zagreb
Riga East University Hospital
Riga Stradins University
Research Center Borstel - Leibniz Lung Center
University of Hamburg
Partner Site Hamburg-Lübeck-Borstel-Riems
Université Paris 13
Queen Mary University of London
Department of Gastroenterology, The Royal London Hospital, Barts Health NHS Trust, London, UK
Vrije Universiteit Amsterdam
Amsterdam Public Health
University of Lübeck
Texas Children's Hospital Houston

Research output: Contribution to journal › Comment/Letter to the editor › Academic

17 Downloads (Pure)

Original language	English
Article number	2200388
Number of pages	3
Journal	European respiratory journal
Volume	59
Issue number	5
DOIs	https://doi.org/10.1183/13993003.00388-2022
Publication status	Published - 1 May 2022
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1183/13993003.00388-2022

Rifapentine-access-in-europe.pdfFinal published version, 668 KBLicence: CC BY

Cite this

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, & Tuberculosis Network European Trials group (TBnet) (2022). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European respiratory journal, 59(5), Article 2200388. https://doi.org/10.1183/13993003.00388-2022

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and ; Tuberculosis Network European Trials group (TBnet). / Rifapentine access in Europe : growing concerns over key tuberculosis treatment component. In: European respiratory journal. 2022 ; Vol. 59, No. 5.

@article{05f51787f3e44b93868c950aec1276c9,

title = "Rifapentine access in Europe: growing concerns over key tuberculosis treatment component",

author = "Lorenzo Guglielmetti and Gunar G{\"u}nther and Claude Leu and Daniela Cirillo and Raquel Duarte and Garcia-Basteiro, \{Alberto L.\} and Delia Goletti and Mateja Jankovic and Liga Kuksa and Maurer, \{Florian P.\} and Fr{\'e}d{\'e}ric M{\'e}cha{\"i} and Simon Tiberi and \{van Leth\}, Frank and Nicolas Veziris and \{Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and\} and \{Tuberculosis Network European Trials group (TBnet)\} and Christoph Lange",

note = "Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.",

year = "2022",

month = may,

day = "1",

doi = "10.1183/13993003.00388-2022",

language = "English",

volume = "59",

journal = "European respiratory journal",

issn = "0903-1936",

publisher = "European Respiratory Society",

number = "5",

}

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and & Tuberculosis Network European Trials group (TBnet) 2022, 'Rifapentine access in Europe: growing concerns over key tuberculosis treatment component', European respiratory journal, vol. 59, no. 5, 2200388. https://doi.org/10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. / Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and; Tuberculosis Network European Trials group (TBnet).
In: European respiratory journal, Vol. 59, No. 5, 2200388, 01.05.2022.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Rifapentine access in Europe

T2 - growing concerns over key tuberculosis treatment component

AU - Guglielmetti, Lorenzo

AU - Günther, Gunar

AU - Leu, Claude

AU - Cirillo, Daniela

AU - Duarte, Raquel

AU - Garcia-Basteiro, Alberto L.

AU - Goletti, Delia

AU - Jankovic, Mateja

AU - Kuksa, Liga

AU - Maurer, Florian P.

AU - Méchaï, Frédéric

AU - Tiberi, Simon

AU - van Leth, Frank

AU - Veziris, Nicolas

AU - Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and

AU - Tuberculosis Network European Trials group (TBnet)

AU - Lange, Christoph

N1 - Funding Information: Support statement: C. Lange is supported by the German Center of Infection Research (DZIF). All other authors have no funding to declare for this study. Funding information for this article has been deposited with the Crossref Funder Registry.

PY - 2022/5/1

Y1 - 2022/5/1

UR - https://www.scopus.com/pages/publications/85130397640

U2 - 10.1183/13993003.00388-2022

DO - 10.1183/13993003.00388-2022

M3 - Comment/Letter to the editor

C2 - 35589114

SN - 0903-1936

VL - 59

JO - European respiratory journal

JF - European respiratory journal

IS - 5

M1 - 2200388

ER -

Study Group on Mycobacteria of the European Society of Microbiology and Infectious Diseases (ESGMYC), European Society of Mycobacteriology (ESM), European Respiratory Society (ERS) and, Tuberculosis Network European Trials group (TBnet). Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. European respiratory journal. 2022 May 1;59(5):2200388. doi: 10.1183/13993003.00388-2022

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

UN SDGs

Access to Document

Other files and links

Cite this